Rituximab infusion reaction and hypogammaglobulinaemia
Biologic infusion and immunoglobulin complications · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Rituximab, widely used in vasculitis, lupus and refractory inflammatory arthritis, commonly causes cytokine-release infusion reactions during the first infusion and can lead to cumulative hypogammaglobulinaemia with infection risk. Reactions range from mild flushing to bronchospasm, hypotension and, rarely, anaphylaxis.
Red flags
- Airway swelling, stridor or bronchospasm
- Hypotension or collapse during infusion
- Recurrent or severe infections (hypogammaglobulinaemia)
- Features of hepatitis B reactivation (deranged LFTs)
- Late rash, fever and arthralgia (serum sickness)
Assessment
Differential diagnosis
- IgE-mediated anaphylaxis
- Cytokine-release (infusion) reaction
- Serum sickness (delayed)
- Underlying sepsis
- Tumour lysis (in lymphoproliferative disease)
- Vasovagal reaction
Investigations
- Observations during infusion (BP, saturations, temperature, airway)
- Serum immunoglobulins (IgG/IgA/IgM) at baseline and before each cycle
- FBC and B-cell/CD19 counts
- Hepatitis B serology (HBsAg, anti-HBc) before treatment
- Tryptase if anaphylaxis suspected
- Infection screen if febrile or recurrent infections
Management
- Pre-medicate before infusion to reduce reactions and start at a slow infusion rate
- For a mild-moderate infusion reaction, pause or slow the infusion and give antihistamine and steroid, then restart slowly
- For severe reaction (airway, hypotension, bronchospasm) stop the infusion and treat as anaphylaxis with adrenaline
- Screen and manage hepatitis B before treatment to prevent reactivation (antiviral prophylaxis if required)
- Monitor immunoglobulins periodically; investigate recurrent infections for secondary hypogammaglobulinaemia
- Treat significant symptomatic hypogammaglobulinaemia with immunoglobulin replacement
- Consider co-trimoxazole prophylaxis against PJP during intensive immunosuppression
- Document the reaction severity and plan premedication/rate for future cycles
Drugs & doses
Methylprednisolone — 100 mg IV premedication 30 min before rituximab infusion
Chlorphenamine — 10 mg IV plus paracetamol 1 g PO as premedication/for mild reactions
Adrenaline — 500 micrograms (0.5 mL of 1:1000) IM for anaphylaxis, repeat after 5 min as needed
Normal immunoglobulin (IVIG) — replacement dosing (e.g. 0.4 g/kg every 3-4 weeks) for symptomatic hypogammaglobulinaemia
Entecavir / tenofovir — antiviral prophylaxis if hepatitis B core antibody positive (specialist-led)
Disposition
Manage mild reactions and continue infusion with monitoring; admit for anaphylaxis, significant infection or immunoglobulin complications.
Complications & pitfalls
- Anaphylaxis / severe infusion reaction
- Secondary hypogammaglobulinaemia with recurrent infection
- Hepatitis B reactivation and fulminant hepatitis
- Progressive multifocal leukoencephalopathy (rare)
- Serum sickness and late neutropenia
Exam pearls
- First-infusion cytokine-release reactions are common - premedicate and infuse slowly
- Always check hepatitis B status before rituximab to prevent reactivation
- Measure immunoglobulins before each cycle; cumulative hypogammaglobulinaemia increases infection risk
- A true infusion reaction usually allows rechallenge at a slower rate, unlike anaphylaxis
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.